Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Impact of Severity of Acute Graft-Versus-Host Disease on Healthcare Resource Utilization, Cost and Outcomes

Nosha Farhadfar, MD, Helen L Leather, Shu Wang, Nathan Burton, Vivian Irizarry Gatell, MD, Robbin Itzler, Ramzi G Salloum, John R. Wingard, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137824

Published: 2020

Journal Articles

Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)

Jack W. Hsu, MD, Nosha Farhadfar, MD, Hemant S. Murthy, MD, Brent Logan, PhD, Stephanie Bo-Subait, MPH, Noelle V. Frey, MD, Steven C. Goldstein, MD, Mary M. Horowitz, MD MS, Hillard M Lazarus, MD, Joshua Schwanke, Nirali N. Shah, MD, Stephen R. Spellman, MS, Galen E. Switzer, PhD, Steven M Devine, MD, Bronwen E. Shaw, PhD MRCP, FRCPath, John R. Wingard, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136778

Published: 2020

Journal Articles

Diet Quality of Long-Term Allogeneic and Autologous Stem Cell Transplant (HCT) Survivors

Nosha Farhadfar, MD, Debra Lynch Kelly, PhD, Lacey E. Mead, BS, Shalini Nair, Randy A. Brown, MD, John W. Hiemenz, MD, Jack W. Hsu, MD, Hemant S. Murthy, MD, W. Stratford May, MD PhD, John R. Wingard, MD, Wendy J Dahl, PhD

Blood (2019) 134 (Supplement_1): 4565.

https://doi.org/10.1182/blood-2019-127648

Published: 2019

Journal Articles

Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)

Nosha Farhadfar, MD, Ajoy L. Dias, MD, Tao Wang, PhD, Caitrin Fretham, Hemant S. Murthy, MD, Brent R. Logan, Shin Mineishi, MD, Bipin N. Savani, MD, Edward A. Stadtmauer, MD FACP, Saurabh Chhabra, MD, John R. Wingard, MD, Siddhartha Ganguly, MD, Marcelo C. Pasquini, MDMS

Blood (2019) 134 (Supplement_1): 3256.

https://doi.org/10.1182/blood-2019-125761

Published: 2019

Journal Articles

Weighty Choices: Selecting Optimal G-CSF Doses for Stem Cell Mobilization to Optimize Yield

Nosha Farhadfar, MD, Jack W. Hsu, MD, Brent R. Logan, PhD, Jennifer A. Sees, MPH, Pintip Chitphakdithai, PhD, Dennis L. Confer, MD, Michael A. Pulsipher, MD, Nirali N. Shah, MD, Galen E. Switzer, PhD, Bronwen E. Shaw, MD PhD, John R. Wingard, MD

Blood (2018) 132 (Supplement 1): 193.

https://doi.org/10.1182/blood-2018-193

Published: 2018

Journal Articles

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Blood (2018) 132 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2018-99-110814

Published: 2018

Journal Articles

Microbiota Phylogenic Analysis Revealed Decreased Abundance of Faecalibacterium Prausnitzii , an Anti-Inflammatory Commensal Bacterium, in Patients with Chronic Graft-Versus-Host Disease

Nosha Farhadfar, MD, Raad Z. Gharaibeh, PhD, John R. Wingard, MD, Debra Lyon, PhD RN, FAAN, Christian Jobin, PhD, Gary P Wang, MD PhD, Michael Raymond Weaver, BA, Hemant S. Murthy, MD, Debra Lynch Kelly, PhD RN, OCN, CNE

Blood (2018) 132 (Supplement 1): 2119.

https://doi.org/10.1182/blood-2018-99-113658

Published: 2018

Journal Articles

Late Fatal Infections Remains Frequent Cause of Mortality in Pediatric Allogeneic Stem Cell Transplant Recipients

Maxim Norkin, MD, Bronwen E. Shaw, PhD MRCP, FRCPath, Ruta Brazauskas, PhD, Heather R. Millard, MPH, Mary E. Flowers, MD, Minoo Battiwalla, MD, Bipin N. Savani, MD, Marcie L. Riches, MDMS, Juan Gea-Banacloche, MD, John R. Wingard, MD

Blood (2017) 130 (Supplement 1): 334.

https://doi.org/10.1182/blood.V130.Suppl_1.334.334

Published: 2017

Journal Articles

Late Fatal Infections Remain Higher Than Expected in Adults Receiving Allogeneic Stem Cell Transplant

Blood (2017) 130 (Supplement 1): 335.

https://doi.org/10.1182/blood.V130.Suppl_1.335.335

Published: 2017

Journal Articles

Efficacy of Early Post-Transplant Vaccination Using a Prime and Boost Strategy Is Independent of a Prior History of GvHD: Results from BMT CTN 0201

Edmund K. Waller, MD, Brent R. Logan, PhD, Mingwei Fei, MS, Alan Howard, PhD, John R. Wingard, MD, Claudio Anasetti, MD, Cynthia R. Giver, PhD

Blood (2017) 130 (Supplement 1): 1972.

https://doi.org/10.1182/blood.V130.Suppl_1.1972.1972

Published: 2017

Journal Articles

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 3910.

https://doi.org/10.1182/blood.V130.Suppl_1.3910.3910

Published: 2017

Journal Articles

Poor Graft Function Following Autologous Stem Cell Transplant (ASCT): A Retrospective Analysis over Two Decades at a Transplant Center

Forat Lutfi, MD, William Paul Skelton, IV, MD, Emma Rosenau, Nosha Farhadfar, MD, Hemant S. Murthy, MD, W. Stratford May, MD PhD, John W. Hiemenz, MD, Christopher R. Cogle, MD, Randy A. Brown, MD, Sarah Wheeler, RPH, John R. Wingard, MD, Maxim Norkin, MD

Blood (2017) 130 (Supplement 1): 4529.

https://doi.org/10.1182/blood.V130.Suppl_1.4529.4529

Published: 2017

Journal Articles

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 4277.

https://doi.org/10.1182/blood.V130.Suppl_1.4277.4277

Published: 2017

Journal Articles

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Blood (2017) 130 (Supplement 1): 2707.

https://doi.org/10.1182/blood.V130.Suppl_1.2707.2707

Published: 2017

Journal Articles

Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic Malignancies

Walter W Grubb, MS, Samuel Huse, BA, Naufil Alam, PhD, Samuel Dychter, MD, John R. Wingard, MD, Navneet S. Majhail, MD MS, Ariel Berger, MPH

Blood (2016) 128 (22): 1187.

https://doi.org/10.1182/blood.V128.22.1187.1187

Published: 2016

Journal Articles

Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma

Prajwol Pathak, MD, Athira Unnikrishnan, MD, Fei Zou, PhD, Helen Leather, BPharm, Christopher R. Cogle, MD, Jack W Hsu, MD, Randy A. Brown, MD, John R. Wingard, MD, Maxim Norkin, MD PhD

Blood (2016) 128 (22): 5832.

https://doi.org/10.1182/blood.V128.22.5832.5832

Published: 2016

Journal Articles

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDS

Leylah Drusbosky, PhD, Elizabeth Wise, BS, Shireen Vali, PhD, Taher Abbasi, Ansu Kumar, Neeraj Kumar Singh, Kabya Basu, Chandan Kumar, Amjad Husain, Fei Zou, PhD, Caitlin Tucker, BS, Randy A Brown, MD, Maxim Norkin, MD PhD, John Hiemenz, MD, John R. Wingard, MD, Jack W Hsu, MD, Christopher R. Cogle, MD

Blood (2016) 128 (22): 594.

https://doi.org/10.1182/blood.V128.22.594.594

Published: 2016

Journal Articles

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Blood (2016) 128 (22): 683.

https://doi.org/10.1182/blood.V128.22.683.683

Published: 2016

Journal Articles

The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS

Shannon Somer Stockton, BA, Leslie Pettiford, RN, MS, CCRC, Christina Cline, RN, BSN, David Chaplin, PhD, Jack W Hsu, John R. Wingard, MD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 4936.

https://doi.org/10.1182/blood.V126.23.4936.4936

Published: 2015

Journal Articles

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Maxim Norkin, MD PhD, Myron Chang, PhD, An Qi, PhD, Helen Leather, BPharm, Lakshmikanth Katragadda, MD, Ying Li, MD PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, John R Wingard, MD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 3852.

https://doi.org/10.1182/blood.V126.23.3852.3852

Published: 2015

NARROW

Impact of Severity of Acute Graft-Versus-Host Disease on Healthcare Resource Utilization, Cost and Outcomes

Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)

Diet Quality of Long-Term Allogeneic and Autologous Stem Cell Transplant (HCT) Survivors

Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)

Weighty Choices: Selecting Optimal G-CSF Doses for Stem Cell Mobilization to Optimize Yield

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Microbiota Phylogenic Analysis Revealed Decreased Abundance of Faecalibacterium Prausnitzii , an Anti-Inflammatory Commensal Bacterium, in Patients with Chronic Graft-Versus-Host Disease

Late Fatal Infections Remains Frequent Cause of Mortality in Pediatric Allogeneic Stem Cell Transplant Recipients

Late Fatal Infections Remain Higher Than Expected in Adults Receiving Allogeneic Stem Cell Transplant

Efficacy of Early Post-Transplant Vaccination Using a Prime and Boost Strategy Is Independent of a Prior History of GvHD: Results from BMT CTN 0201

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Poor Graft Function Following Autologous Stem Cell Transplant (ASCT): A Retrospective Analysis over Two Decades at a Transplant Center

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic Malignancies

Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDS

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only